NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions in children and adults, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference. The virtual event will take place on May 29, 2025.
The company will deliver a webcast presentation at 9:30 a.m. ET and conduct one-on-one meetings with investors throughout the event. Interested parties can access the webcast through the conference website or directly via the provided link, with replay options available after the event.
NeurAxis (NYSE American: NRXS), un'azienda tecnologica medica specializzata in terapie di neuromodulazione per condizioni croniche in bambini e adulti, ha annunciato la sua partecipazione alla prossima Conferenza per Investitori Lytham Partners Primavera 2025. L'evento virtuale si terrà il 29 maggio 2025.
L'azienda terrà una presentazione in webcast alle 9:30 a.m. ET e svolgerà incontri individuali con gli investitori durante tutta la conferenza. Gli interessati potranno accedere al webcast tramite il sito web della conferenza o direttamente tramite il link fornito, con la possibilità di rivedere la registrazione dopo l'evento.
NeurAxis (NYSE American: NRXS), una empresa de tecnología médica enfocada en terapias de neuromodulación para condiciones crónicas en niños y adultos, ha anunciado su participación en la próxima Conferencia de Inversores Lytham Partners Primavera 2025. El evento virtual se llevará a cabo el 29 de mayo de 2025.
La compañía realizará una presentación por webcast a las 9:30 a.m. ET y llevará a cabo reuniones individuales con inversionistas durante todo el evento. Las personas interesadas podrán acceder al webcast a través del sitio web de la conferencia o directamente mediante el enlace proporcionado, con opciones de reproducción disponibles después del evento.
NeurAxis (NYSE American: NRXS)는 어린이와 성인의 만성 질환을 위한 신경조절 치료에 중점을 둔 의료 기술 회사로, 다가오는 2025년 봄 Lytham Partners 투자자 컨퍼런스에 참여한다고 발표했습니다. 이 가상 행사는 2025년 5월 29일에 개최됩니다.
회사는 동부 표준시 오전 9시 30분에 웹캐스트 프레젠테이션을 진행하며, 행사 기간 동안 투자자들과 일대일 미팅도 진행할 예정입니다. 관심 있는 분들은 컨퍼런스 웹사이트나 제공된 링크를 통해 웹캐스트에 접속할 수 있으며, 행사 후 재시청도 가능합니다.
NeurAxis (NYSE American : NRXS), une société de technologie médicale spécialisée dans les thérapies de neuromodulation pour les affections chroniques chez les enfants et les adultes, a annoncé sa participation à la prochaine Conférence des investisseurs Lytham Partners Printemps 2025. L'événement virtuel aura lieu le 29 mai 2025.
La société présentera un webcast à 9h30 ET et tiendra des réunions individuelles avec les investisseurs tout au long de l'événement. Les personnes intéressées pourront accéder au webcast via le site web de la conférence ou directement via le lien fourni, avec des options de rediffusion disponibles après l'événement.
NeurAxis (NYSE American: NRXS), ein Medizintechnologieunternehmen, das sich auf Neuromodulationstherapien für chronische Erkrankungen bei Kindern und Erwachsenen spezialisiert hat, hat seine Teilnahme an der bevorstehenden Lytham Partners Frühling 2025 Investorenkonferenz angekündigt. Die virtuelle Veranstaltung findet am 29. Mai 2025 statt.
Das Unternehmen wird um 9:30 Uhr ET eine Webcast-Präsentation halten und während der gesamten Veranstaltung Einzelgespräche mit Investoren führen. Interessierte können den Webcast über die Konferenz-Website oder direkt über den bereitgestellten Link verfolgen, mit der Möglichkeit, die Aufzeichnung nach der Veranstaltung anzusehen.
- None.
- None.
CARMEL, Ind., May 27, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025.
Company Webcast
The webcast presentation will take place at 9:30 a.m. ET on Thursday, May 29, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2025/ or directly at https://app.webinar.net/qdroK7R5BZy. The webcast will also be available for replay following the event.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout thae event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/spring2025invreg/.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, the results of the shareholder vote to enable the issuance of the Preferred Stock, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contacts:
Company
NeurAxis, Inc.
info@neuraxis.com
Investor Relations
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
FAQ
When is NeurAxis (NRXS) presenting at the Lytham Partners Spring 2025 Conference?
How can investors access the NeurAxis (NRXS) presentation at the Lytham Conference?
How can investors arrange one-on-one meetings with NeurAxis (NRXS) management?
What type of medical technology does NeurAxis (NRXS) develop?
